What does BOSLY ENDOCRINOLOGIE ET NUTRITION do?

BOSLY ENDOCRINOLOGIE ET NUTRITION is a research organisation in Arlon. Private Limited, started on 9 November 2009, 1 establishment.

What is the address of BOSLY ENDOCRINOLOGIE ET NUTRITION?

The registered office of BOSLY ENDOCRINOLOGIE ET NUTRITION is located at Udange, rue de Habergy 30, 6700 Arlon.

Is BOSLY ENDOCRINOLOGIE ET NUTRITION still active?

Yes. According to the CBE (30 September 2026) BOSLY ENDOCRINOLOGIE ET NUTRITION is active, legal situation “Normale toestand”, started on 9 November 2009.

Is BOSLY ENDOCRINOLOGIE ET NUTRITION registered on Peppol?

Yes, BOSLY ENDOCRINOLOGIE ET NUTRITION is registered on the Peppol network with ID 0208:0820413231.

What is the enterprise number of BOSLY ENDOCRINOLOGIE ET NUTRITION?

The enterprise number of BOSLY ENDOCRINOLOGIE ET NUTRITION is BE0820413231.

When was BOSLY ENDOCRINOLOGIE ET NUTRITION founded?

BOSLY ENDOCRINOLOGIE ET NUTRITION was founded on 9 November 2009.

Who are the directors of BOSLY ENDOCRINOLOGIE ET NUTRITION?

According to the 2025 annual accounts, the directors of BOSLY ENDOCRINOLOGIE ET NUTRITION are: Florence BOSLY.

Is BOSLY ENDOCRINOLOGIE ET NUTRITION a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 November 2009; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did BOSLY ENDOCRINOLOGIE ET NUTRITION make in 2025?

BOSLY ENDOCRINOLOGIE ET NUTRITION posted a profit after taxes of € 102,219 in financial year 2025.

What is the revenue of BOSLY ENDOCRINOLOGIE ET NUTRITION?

As a small company, BOSLY ENDOCRINOLOGIE ET NUTRITION is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 130,994.

BOSLY ENDOCRINOLOGIE ET NUTRITION (Private Limited)

Dossier BOSLY ENDOCRINOLOGIE ET NUTRITION, printed on 30 September 2026 from databakkes.be/en/0820413231/bosly-endocrinologie-et-nutrition. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

BOSLY ENDOCRINOLOGIE ET NUTRITION from Arlon, company number BE0820413231, closed financial year 2025 with a result of € 102,219 after tax. For that financial year BOSLY ENDOCRINOLOGIE ET NUTRITION recorded a gross margin of € 130,994 and equity of € 939,288. Compared with financial year 2024, the result moved from € 86,320 to € 102,219. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 7, 2026.

What it is worth Growing

€ 939,288

▲ 12% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 102,219

▲ 18% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 165,647

▲ 234% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 833 paid out

1 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 602

▲ 82% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 601

▲ 176% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 43,424

▲ 11% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 111,041 Gross margin 2022: € 111,041 First fiscal year in the series	€ 122,192 Gross margin 2023: € 122,192 ▲ 10% vs 2022 (€ 111,041) Favourable step	€ 116,330 Gross margin 2024: € 116,330 ▼ 5% vs 2023 (€ 122,192) Unfavourable step	€ 130,994 Gross margin 2025: € 130,994 ▲ 13% vs 2024 (€ 116,330) Favourable step	▲ 13%
Profit after taxes	€ 76,405 Profit after taxes 2022: € 76,405 First fiscal year in the series	€ 79,570 Profit after taxes 2023: € 79,570 ▲ 4% vs 2022 (€ 76,405) Favourable step	€ 86,320 Profit after taxes 2024: € 86,320 ▲ 8% vs 2023 (€ 79,570) Favourable step	€ 102,219 Profit after taxes 2025: € 102,219 ▲ 18% vs 2024 (€ 86,320) Favourable step	▲ 18%
Equity	€ 723,645 Equity 2022: € 723,645 First fiscal year in the series	€ 802,416 Equity 2023: € 802,416 ▲ 11% vs 2022 (€ 723,645) Favourable step	€ 837,903 Equity 2024: € 837,903 ▲ 4% vs 2023 (€ 802,416) Favourable step	€ 939,288 Equity 2025: € 939,288 ▲ 12% vs 2024 (€ 837,903) Favourable step	▲ 12%
Total debts	€ 38,815 Total debts 2022: € 38,815 First fiscal year in the series	€ 42,334 Total debts 2023: € 42,334 ▲ 9% vs 2022 (€ 38,815) Unfavourable step	€ 44,483 Total debts 2024: € 44,483 ▲ 5% vs 2023 (€ 42,334) Unfavourable step	€ 46,571 Total debts 2025: € 46,571 ▲ 5% vs 2024 (€ 44,483) Unfavourable step	▲ 5%
Cash	€ 414,420 Cash 2022: € 414,420 First fiscal year in the series	€ 125,333 Cash 2023: € 125,333 ▼ 70% vs 2022 (€ 414,420) Unfavourable step	€ 49,639 Cash 2024: € 49,639 ▼ 60% vs 2023 (€ 125,333) Unfavourable step	€ 165,647 Cash 2025: € 165,647 ▲ 234% vs 2024 (€ 49,639) Favourable step	▲ 234%
Land & buildings	€ 127,028 Land & buildings 2022: € 127,028 First fiscal year in the series	€ 120,886 Land & buildings 2023: € 120,886 ▼ 5% vs 2022 (€ 127,028) Unchanged	€ 114,743 Land & buildings 2024: € 114,743 ▼ 5% vs 2023 (€ 120,886) Unchanged	€ 108,601 Land & buildings 2025: € 108,601 ▼ 5% vs 2024 (€ 114,743) Unchanged	▼ 5%
Retained profit	€ 603,172 Retained profit 2022: € 603,172 First fiscal year in the series	€ 669,285 Retained profit 2023: € 669,285 ▲ 11% vs 2022 (€ 603,172) Favourable step	€ 704,773 Retained profit 2024: € 704,773 ▲ 5% vs 2023 (€ 669,285) Favourable step	€ 806,158 Retained profit 2025: € 806,158 ▲ 14% vs 2024 (€ 704,773) Favourable step	▲ 14%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 800 Dividend 2023: € 800 Unchanged (€ 800) Unchanged	€ 50,833 Dividend 2024: € 50,833 ▲ € 50,033 vs 2023 (€ 800) Unchanged	€ 833 Dividend 2025: € 833 ▼ 98% vs 2024 (€ 50,833) Unchanged	▼ 98%
Bank debt	€ 1,150 Bank debt 2022: € 1,150 First fiscal year in the series	€ 1,150 Bank debt 2023: € 1,150 Unchanged (€ 1,150) Unchanged	€ 1,150 Bank debt 2024: € 1,150 Unchanged (€ 1,150) Unchanged	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 1,150) Favourable step	▼ 100%
Balance sheet total	€ 762,460 Balance sheet total 2022: € 762,460 First fiscal year in the series	€ 844,749 Balance sheet total 2023: € 844,749 ▲ 11% vs 2022 (€ 762,460) Unchanged	€ 882,385 Balance sheet total 2024: € 882,385 ▲ 4% vs 2023 (€ 844,749) Unchanged	€ 985,860 Balance sheet total 2025: € 985,860 ▲ 12% vs 2024 (€ 882,385) Unchanged	▲ 12%

Key figures of BOSLY ENDOCRINOLOGIE ET NUTRITION, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BOSLY ENDOCRINOLOGIE ET NUTRITION?

What happened at BOSLY ENDOCRINOLOGIE ET NUTRITION in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 7, 2026 New annual accounts for financial year 2025: profit of € 102,219 (▲ 18% vs 2024). filed late Source: NBB ↗
Nov 9, 2009 Start of the company according to the CBE. KBO
Oct 27, 2009 New establishment in Arlon. KBO

In short

From € 76,405 profit in 2022 to € 102,219 profit in 2025.

Paid € 139,644 in corporate taxes since 2022.

Best year ever: 2025, with € 102,219 profit.

Paid out € 53,266 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at BOSLY ENDOCRINOLOGIE ET NUTRITION? We notify you, reason included.

Follow BOSLY ENDOCRINOLOGIE ET NUTRITION

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Florence BOSLY

BOSLY ENDOCRINOLOGIE ET NUTRITION

Behind BOSLY ENDOCRINOLOGIE ET NUTRITION is Florence BOSLY.

See the full network in the app

Directors

According to the 2025 annual accounts

Florence BOSLY

Manager

Establishments

Establishment units

Physical locations of this company

Registered office

Udange, rue de Habergy 30

6700 Arlon

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0820.413.231

VAT number

BE 0820.413.231

Registered office

Udange, rue de Habergy 30, 6700 Arlon

Names & denominations

BOSLY ENDOCRINOLOGIE ET NUTRITION · "B.E.N" S.R.L

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 November 2009

Peppol

Active · Active since 26 Sept 2025

Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗